Motus GI Holdings Valuation

Is MOTS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOTS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MOTS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MOTS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOTS?

Key metric: As MOTS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MOTS. This is calculated by dividing MOTS's market cap by their current revenue.
What is MOTS's PS Ratio?
PS Ratio	0.02x
Sales	US$327.00k
Market Cap	US$5.75k

MOTS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MOTS's PS Ratio compare to its peers?

The above table shows the PS ratio for MOTS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.007x
LHDX.Q Lucira Health	0.00002x	n/a	US$4.2k
THMO ThermoGenesis Holdings	0.001x	n/a	US$7.9k
VRAY.Q ViewRay	0.0002x	n/a	US$18.3k
FORZ Forza Innovations	0.03x	n/a	US$2.6k
MOTS Motus GI Holdings	0.02x	n/a	US$5.8k

Price-To-Sales vs Peers: MOTS is expensive based on its Price-To-Sales Ratio (0x) compared to the peer average (0x).

Price to Sales Ratio vs Industry

How does MOTS's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	3.2x	8.3%
MOTS Motus GI Holdings	0.02x	n/a	US$5.75k
INGN Inogen	0.7x	4.2%	US$225.32m
ARAY Accuray	0.4x	5.5%	US$184.03m

50 Companies		Estimated Growth	Market Cap
Industry Avg.	3.2x	17.0%
MOTS Motus GI Holdings	0.02x	n/a	US$5.75k

No more companies

Price-To-Sales vs Industry: MOTS is good value based on its Price-To-Sales Ratio (0x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is MOTS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOTS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.02x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MOTS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$6.0b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$87.32

8.0%

27.8%

Centene

US$29.8b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.35

2.8%

-18.7%

electroCore

US$64.1m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$9.92

-27.1%

80.4%